Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Takao Itoi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9433-8437; OpenAlex author ID A5019511806, A5060787187, A5138015920. Sources: OpenAlex.

Their work

Papers
44 (first author 5, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
140
Papers, trials and grants by year

2012: 3 papers · 2013: 3 papers · 2014: 2 papers · 2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: 4 papers · 2019: 3 papers · 2020: 2 papers · 2021: 3 papers · 2022: 4 papers · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers · 2026: 7 papers

Papers 44

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  3. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Co-author DOI 10.1016/j.gie.2026.05.032↗
  4. Artificial intelligence-assisted endoscopic ultrasonography for the detection of a small T1 pancreatic ductal adenocarcinoma in a difficult-to-puncture locatio… Last author DOI 10.1055/a-2944-3582↗
  5. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  6. Preoperative Biliary Drainage with Metal Stent Versus Early Surgery in Patients with Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1245/s10434-026-19546-9↗
  7. Prognostic value of lactate dehydrogenase-to-albumin ratio in metastatic/recurrent pancreatic cancer treated with first-line gemcitabine plus nab-paclitaxel: a… Last author DOI 10.21037/jgo-2026-0223↗
  8. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  9. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  10. Evaluating the Usefulness of the Blood Apolipoprotein A2 Isoform Index for Pancreatic Cancer Diagnosis. Last author DOI 10.3390/cancers17071071↗
  11. Identifying predictors for comorbidities related mortality versus pancreatic cancer related mortality in patients with intraductal papillary mucinous neoplasm. Co-author DOI 10.1002/ueg2.12540↗
  12. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  13. STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancr… Co-author DOI 10.1016/j.eclinm.2022.101731↗
  14. A fatal case of massive hemobilia caused by invasive pancreatic cancer with median arcuate ligament syndrome: A case report. Last author DOI 10.1097/md.0000000000035701↗
  15. Fully covered metal stents vs plastic stents for preoperative biliary drainage in patients with resectable pancreatic cancer without neoadjuvant chemotherapy: … Last author DOI 10.1002/jhbp.1090↗
  16. High-intensity focused ultrasound therapy for pancreatic cancer. Last author DOI 10.1007/s10396-022-01208-4↗
  17. Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer From a Multinational Study. Co-author DOI 10.1053/j.gastro.2022.03.054↗
  18. Circulating cancer-associated extracellular vesicles as early detection and recurrence biomarkers for pancreatic cancer. Co-author DOI 10.1111/cas.15500↗
  19. Deep learning analysis for the detection of pancreatic cancer on endosonographic images: a pilot study. First author DOI 10.1002/jhbp.825↗
  20. Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19. Last author DOI 10.2169/internalmedicine.6294-20↗
  21. Novel Therapeutic Method for Unresectable Pancreatic Cancer-The Impact of the Long-Term Research in Therapeutic Effect of High-Intensity Focused Ultrasound (HI… Last author DOI 10.3390/curroncol28060409↗
  22. Pre-aspiration of a large retention cyst followed by EUS-FNB for the successful diagnosis of a patient with pancreatic cancer. First author DOI 10.1002/jhbp.836↗
  23. Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000001579↗
  24. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nat… Co-author DOI 10.1016/j.surg.2019.06.023↗
  25. A Case of Unresectable Pancreatic Cancer with Long-Term Survival in High-Intensity Focused Ultrasound (HIFU) Therapy. Last author DOI 10.1055/a-1061-7790↗
  26. Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic canc… Co-author DOI 10.4103/eus.eus_16_19↗
  27. Surgical Outcomes of Pancreaticoduodenectomy for Pancreatic Cancer with Proximal Dorsal Jejunal Vein Involvement. Co-author DOI 10.1007/s11605-018-3722-0↗
  28. Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreati… Co-author DOI 10.1016/j.gie.2017.10.030↗
  29. Irreversible Electroporation for Nonthermal Tumor Ablation in Patients with Locally Advanced Pancreatic Cancer: Initial Clinical Experience in Japan. Last author DOI 10.2169/internalmedicine.0861-18↗
  30. Elevated Polyamines in Saliva of Pancreatic Cancer. First author DOI 10.3390/cancers10020043↗
  31. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2016.436↗
  32. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination. Co-author DOI 10.3390/ijms18040767↗
  33. Pancreatic cancer. Co-author DOI 10.1016/s0140-6736(16)00141-0↗
  34. Clinicopathological Characteristics of Young Patients With Pancreatic Cancer: An Analysis of Data From Pancreatic Cancer Registry of Japan Pancreas Society. Co-author DOI 10.1097/mpa.0000000000000636↗
  35. Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. Co-author DOI 10.3892/ijo.2015.3237↗
  36. [The strategy of pancreatic cancer for early detection]. First author DOI 10.11405/nisshoshi.112.1484↗
  37. EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Co-author DOI 10.1093/jjco/hyu127↗
  38. Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer. Last author DOI 10.3748/wjg.v20.i28.9570↗
  39. Endoscopic double stenting for the treatment of malignant biliary and duodenal obstruction due to pancreatic cancer. First author DOI 10.1111/den.12063↗
  40. Endoscopic ultrasound-guided choledochoantrostomy as an alternative extrahepatic bile duct drainage method in pancreatic cancer with duodenal invasion. Co-author DOI 10.1111/den.12065↗
  41. Endoscopic ultrasonography-guided cholecystogastrostomy using a lumen-apposing metal stent as an alternative to extrahepatic bile duct drainage in pancreatic c… Co-author DOI 10.1111/den.12084↗
  42. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinic… Co-author DOI 10.1007/s00280-012-1822-1↗
  43. Single nucleotide polymorphism of multidrug-resistance 1 and anti- multidrug-resistance 1 single chain antibody treatment for the pancreatic cancer cell line. Co-author DOI 10.5754/hge11377↗
  44. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism an… Co-author DOI 10.5754/hge11729↗

Closest collaborators

The 25 strongest of 140 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuntaro Mukai · 13 shared papers, 2014–2026 · strength 1.75
  2. Atsushi Sofuni · 15 shared papers, 2012–2026 · strength 1.66
  3. Yuichi Nagakawa · 11 shared papers, 2012–2026 · strength 1.29
  4. Kenjiro Yamamoto · 9 shared papers, 2015–2025 · strength 1.15
  5. Yukitoshi Matsunami · 7 shared papers, 2018–2026 · strength 1.10
  6. Sohei Satoi · 7 shared papers, 2016–2026 · strength 1.10
  7. Ryosuke Tonozuka · 12 shared papers, 2013–2025 · strength 1.07
  8. Shinichi Egawa · 7 shared papers, 2014–2026 · strength 1.04
  9. Michiaki Unno · 6 shared papers, 2016–2026 · strength 1.02
  10. Reina Tanaka · 10 shared papers, 2013–2025 · strength 0.91
  11. Atsushi Masamune · 6 shared papers, 2016–2026 · strength 0.91
  12. Kazumasa Nagai · 6 shared papers, 2019–2026 · strength 0.90
  13. Yoshifumi Takeyama · 4 shared papers, 2025–2026 · strength 0.90
  14. Shin Hamada · 5 shared papers, 2016–2026 · strength 0.82
  15. Masamichi Mizuma · 5 shared papers, 2016–2026 · strength 0.82
  16. Kohei Nakata · 3 shared papers, 2026 · strength 0.71
  17. Ichiro Yasuda · 3 shared papers, 2026 · strength 0.71
  18. Ken Shirabe · 3 shared papers, 2026 · strength 0.71
  19. Kazuichi Okazaki · 4 shared papers, 2019–2026 · strength 0.62
  20. Yasutsugu Asai · 5 shared papers, 2018–2022 · strength 0.56
  21. Yuzo Kodama · 2 shared papers, 2026 · strength 0.48
  22. Manabu Kawai · 2 shared papers, 2026 · strength 0.47
  23. Yoshiya Yamauchi · 1 shared paper, 2026 · strength 0.43
  24. Naoyoshi Nagata · 3 shared papers, 2021–2024 · strength 0.43
  25. Masaji Tani · 5 shared papers, 2012–2025 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.